Engineering antibodies for dual specificity and enhanced potency

Sanghwan Ko, Sang Taek Jung

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Despite the tremendous success of monoclonal antibodies for human therapeutics, there remain several diseases that escape monospecific IgG antibody-mediated immunotherapy. However, the recent in-depth understanding of antibody structure and function, and significant advances in antibody engineering techniques, have facilitated the development of unnatural bispecific antibodies, which are capable of recruiting more powerful effector cells, retargeting target cells, and blocking two different disease mechanisms simultaneously. Conventionally, bispecific antibodies were generated by the fusion of two different hybridoma cells or chemical coupling of two monospecific antibodies. Recently, however, versatile genetic approaches have been devised to produce more homogenous and correctly assembled bispecific antibodies. To ensure improved efficacy, safety, and efficient manufacturing, a variety of strategies to create bispecific antibody fragments and native IgG-like bispecific antibody formats have been developed and are discussed in this review.

Original languageEnglish
Article number1
Pages (from-to)201-210
Number of pages10
JournalBiotechnology and Bioprocess Engineering
Volume20
Issue number2
DOIs
Publication statusPublished - 2015 Apr 22
Externally publishedYes

Fingerprint

Bispecific Antibodies
Antibody Specificity
Antibodies
Immunoglobulin G
Immunoglobulin Fragments
Hybridomas
Immunotherapy
Fusion reactions
Monoclonal Antibodies
Monoclonal antibodies
Safety

Keywords

  • antibody engineering
  • bispecific antibody
  • dual specificity
  • therapeutic antibody

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Biomedical Engineering

Cite this

Engineering antibodies for dual specificity and enhanced potency. / Ko, Sanghwan; Jung, Sang Taek.

In: Biotechnology and Bioprocess Engineering, Vol. 20, No. 2, 1, 22.04.2015, p. 201-210.

Research output: Contribution to journalReview article

@article{143563e3afe4445d8c5d2900b8cd3b1f,
title = "Engineering antibodies for dual specificity and enhanced potency",
abstract = "Despite the tremendous success of monoclonal antibodies for human therapeutics, there remain several diseases that escape monospecific IgG antibody-mediated immunotherapy. However, the recent in-depth understanding of antibody structure and function, and significant advances in antibody engineering techniques, have facilitated the development of unnatural bispecific antibodies, which are capable of recruiting more powerful effector cells, retargeting target cells, and blocking two different disease mechanisms simultaneously. Conventionally, bispecific antibodies were generated by the fusion of two different hybridoma cells or chemical coupling of two monospecific antibodies. Recently, however, versatile genetic approaches have been devised to produce more homogenous and correctly assembled bispecific antibodies. To ensure improved efficacy, safety, and efficient manufacturing, a variety of strategies to create bispecific antibody fragments and native IgG-like bispecific antibody formats have been developed and are discussed in this review.",
keywords = "antibody engineering, bispecific antibody, dual specificity, therapeutic antibody",
author = "Sanghwan Ko and Jung, {Sang Taek}",
year = "2015",
month = "4",
day = "22",
doi = "10.1007/s12257-014-0575-6",
language = "English",
volume = "20",
pages = "201--210",
journal = "Biotechnology and Bioprocess Engineering",
issn = "1226-8372",
publisher = "Korean Society for Biotechnology and Bioengineering",
number = "2",

}

TY - JOUR

T1 - Engineering antibodies for dual specificity and enhanced potency

AU - Ko, Sanghwan

AU - Jung, Sang Taek

PY - 2015/4/22

Y1 - 2015/4/22

N2 - Despite the tremendous success of monoclonal antibodies for human therapeutics, there remain several diseases that escape monospecific IgG antibody-mediated immunotherapy. However, the recent in-depth understanding of antibody structure and function, and significant advances in antibody engineering techniques, have facilitated the development of unnatural bispecific antibodies, which are capable of recruiting more powerful effector cells, retargeting target cells, and blocking two different disease mechanisms simultaneously. Conventionally, bispecific antibodies were generated by the fusion of two different hybridoma cells or chemical coupling of two monospecific antibodies. Recently, however, versatile genetic approaches have been devised to produce more homogenous and correctly assembled bispecific antibodies. To ensure improved efficacy, safety, and efficient manufacturing, a variety of strategies to create bispecific antibody fragments and native IgG-like bispecific antibody formats have been developed and are discussed in this review.

AB - Despite the tremendous success of monoclonal antibodies for human therapeutics, there remain several diseases that escape monospecific IgG antibody-mediated immunotherapy. However, the recent in-depth understanding of antibody structure and function, and significant advances in antibody engineering techniques, have facilitated the development of unnatural bispecific antibodies, which are capable of recruiting more powerful effector cells, retargeting target cells, and blocking two different disease mechanisms simultaneously. Conventionally, bispecific antibodies were generated by the fusion of two different hybridoma cells or chemical coupling of two monospecific antibodies. Recently, however, versatile genetic approaches have been devised to produce more homogenous and correctly assembled bispecific antibodies. To ensure improved efficacy, safety, and efficient manufacturing, a variety of strategies to create bispecific antibody fragments and native IgG-like bispecific antibody formats have been developed and are discussed in this review.

KW - antibody engineering

KW - bispecific antibody

KW - dual specificity

KW - therapeutic antibody

UR - http://www.scopus.com/inward/record.url?scp=84929454314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929454314&partnerID=8YFLogxK

U2 - 10.1007/s12257-014-0575-6

DO - 10.1007/s12257-014-0575-6

M3 - Review article

VL - 20

SP - 201

EP - 210

JO - Biotechnology and Bioprocess Engineering

JF - Biotechnology and Bioprocess Engineering

SN - 1226-8372

IS - 2

M1 - 1

ER -